Prelude Therapeutics Q2 2022 net loss $27.4M; cash $246.3M; IND accepted for CDK4/6 inhibitor PRT3645

Prelude Therapeutics Inc

2022-Q2 EPS reported -$1.20

Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.
Cash, equivalents, and marketable securities $246.3M as of June 30, 2022; funds operations into H2 2024.
FDA accepted IND for brain-penetrant CDK4/6 inhibitor PRT3645; Phase 1 to begin Q4 2022 in multiple cancers.
PRMT5 (PRT811) expansion cohort data readout and next steps expected H2 2022; MCL1 combo data by end of 2022.
SMARCA2/BRM degrader program on track to file IND by year-end 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.